Loading organizations...
Based in Albuquerque, New Mexico, BioFlyte develops and commercializes fieldable aerosol mass spectrometers for the real-time detection of biological and chemical threats. The company's flagship hardware products, including the BioTOF z200 and MAILSCREEN z200, autonomously sample air and parcels in critical infrastructure environments to identify hazards like fentanyl, viruses, and bio-toxins in under five minutes. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the firm recently secured a Department of Homeland Security SAFETY Act Designation. BioFlyte has raised $12.8 million in venture capital funding, which includes a $5.4 million Series B financing round led by Scout Ventures with participation from Cottonwood Technology Fund and Anzu Partners. While the specific founding year remains undisclosed, the organization recently expanded its leadership team by appointing Clark Griffin as Vice President of Engineering.
BioFlyte has raised $12.3M across 3 funding rounds.
BioFlyte has raised $12.3M in total across 3 funding rounds.
BioFlyte has raised $12.3M across 3 funding rounds. Most recently, it raised $5.0M Series B in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2023 | $5M Series B | Scout Ventures, Cottonwood Technology Fund | NEW York Ventures, Salesforce Ventures, NEW Mexico Vintage Fund | Announced |
| Apr 1, 2022 | $6M Series A | Cottonwood Technology Fund | Mountain Group Partners, Jenna Abelli | Announced |
| Jun 10, 2020 | $1.3M Seed | David Seldin | — | Announced |
BioFlyte has raised $12.3M in total across 3 funding rounds.
BioFlyte's investors include Scout Ventures, Cottonwood Technology Fund, New York Ventures, Salesforce Ventures, New Mexico Vintage Fund, Mountain Group Partners, Jenna Abelli, David Seldin.
BioFlyte is a biothreat security company developing fieldable aerosol mass spectrometers for real-time detection and identification of biological and chemical threats like Anthrax, Ricin, viruses, spores, and aerosolized Fentanyl.[1][2][3] It serves critical infrastructure operators, government agencies, airports, and mail screening services by protecting against biohazards and chemical toxins without relying on expensive reagents, enabling autonomous operation for months.[1][2][4] The company's growth includes $12.8M in total funding, partnerships with entities like Pittsburgh International Airport and the Pentagon Force Protection Agency, and a recent U.S. Department of Homeland Security SAFETY Act Designation in August 2025, positioning it for market penetration in high-stakes environments like major U.S. airports.[2][3][5]
BioFlyte, headquartered in Albuquerque, New Mexico, commercializes miniaturized, low-cost, low-power mass spectrometers originally rooted in advanced biodefense technologies for airborne microbial and toxin detection.[3][4] Led by President & CEO Todd Sickles and Chief Science Officer Wayne Bryden, Ph.D., the company has deep ties to New Mexico's tech ecosystem, including local government labs and Sandia Science & Technology Park.[1][4][5] Its evolution focuses on critical infrastructure protection and pandemic response, with early traction from evaluations by defense agencies and commercial partners like SoBran, Inc., culminating in the BioTOF™ system's deployment for mail screening and airport security.[2][3][5]
BioFlyte rides the surging demand for biothreat surveillance amid rising geopolitical tensions, pandemics, and synthetic opioid crises, enabling point-of-need detection in transportation hubs, mailrooms, and public venues.[1][2][3] Timing aligns with post-COVID infrastructure investments and U.S. homeland security priorities, as seen in its DHS designation and airport expansion goals.[1][5] Market forces like fentanyl aerosol risks and bioterrorism threats favor its reagent-free, real-time edge over legacy systems, influencing the ecosystem by partnering with labs and agencies to set new standards for scalable chem/bio defense.[2][4][5]
BioFlyte's near-term priority is securing at least one major U.S. airport contract within 12 months, leveraging its New Mexico roots for talent and partnerships to drive revenue beyond $5M recent funding.[1][3] Escalating global bio-risks and AI-enhanced threat libraries will shape its path, potentially expanding to more commercial sites and international markets. As a validated player in biodefense, BioFlyte could redefine critical infrastructure protection, scaling its "revolutionary" spectrometers from niche security to widespread biosecurity at scale.[2][5]
